Month: September 2026

Late-breaking presentation will highlight Phase 2b clinical data for MAR001, a potential first-in-class antibody targeting ANGPTL4 designed to lower triglycerides and improve metabolic function

SOUTH SAN FRANCISCO and LIBERTY CORNER, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) — Marea Therapeutics, Inc. (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that data from the Phase 2b TYDAL study of MAR001, a potential first-in-class monoclonal antibody targeting angiopoietin-like protein 4 (ANGPTL4), will be presented in a late-breaking science session at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6-9, 2026, in Chicago, Illinois.

Presentation details are as follows:

Title: TYDAL-TIMI 78: A Randomized Trial of ANGPTL4 Inhibition With MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol Concentrations
Session: LBS.05: Late-breaking Science: New Frontiers in Cardiometabolic Risk Reduction
Date/Time: Monday, November 9, 2026, 8:00 a.m. CT

About MAR001/005
MAR001 is a potential first-in-class monoclonal antibody in clinical development that targets ANGPTL4, a protein that is highly expressed in adipose tissue. By inhibiting ANGPTL4 and thereby augmenting lipoprotein lipase (LPL) activity, MAR001 is designed to lower triglycerides and improve adipose tissue function. Human genetic data has identified ANGPTL4 as a highly promising therapeutic target because loss of function alleles lead to lower triglyceride levels, improved adipose distribution, better insulin sensitivity, and protection from cardiovascular disease and type 2 diabetes.

MAR005, a half-life-extended version of MAR001 with an improved pharmacokinetic profile, is Marea’s planned Phase 3 candidate and is in clinical development for the treatment of severe hypertriglyceridemia (sHTG), a condition characterized by very high triglyceride levels. Preclinical models with MAR001 demonstrated reduction in triglycerides, remnant cholesterol and ectopic fat, and improved insulin sensitivity. MAR001 has demonstrated strong Phase 1 and 2a results and is in Phase 2b clinical development.  

About Marea Therapeutics
Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases. The company’s lead product candidate, MAR001, is in Phase 2b clinical development for the treatment of severe hypertriglyceridemia (sHTG), a condition characterized by very high triglyceride levels. The company is also advancing MAR002 for the treatment of acromegaly.

About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company. Following its acquisition of Marea, Lisata’s lead product candidate is MAR001, which is in Phase 2b clinical development for the treatment of severe hypertriglyceridemia (sHTG), a condition characterized by very high triglyceride levels. The company is also advancing MAR002 for the treatment of acromegaly.

Cautionary Note Regarding Forward-Looking Statements
Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, concerning Lisata and Marea, including the acquisition of Marea by Lisata (the “Transaction”) and other matters. These forward-looking statements include, but are not limited to, express or implied statements relating to the company’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding expectations regarding or plans for the company’s pipeline, including its ongoing clinical trials, research and development programs and the expected timing for key milestones; and the potential benefits of MAR001/005 and MAR002. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “aim,” “strategy,” “target,” “seek,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “predict,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting the company or the Transaction will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the company’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to those uncertainties and factors described under the heading “Risk Factors” in the company’s most recent Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 12, 2026, as well as discussions of potential risks, uncertainties, and other important factors included in other filings by the company from time to time, as well as risk factors associated with companies, such as Marea, that operate in the biotechnology industry. Should one or more of these risks or uncertainties materialize, or should any of the company’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. The company does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in the company.

Contacts:

Lisata:

Investors and Media:
John Menditto
jmenditto@lisata.com

Marea:

Media:
1AB
Katie Engleman
katie@1abmedia.com   

Investors:
Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com

Fort Lee, NJ, Sept. 24, 2026 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, announced today that NXP200 (HSK42360), an oral, brain-penetrant, paradox-breaker BRAF inhibitor, has been granted Breakthrough Therapy Designation (BTD) for the treatment of patients with BRAF V600-mutant, recurrent or progressive high-grade glioma by China’s Center for Drug Evaluation (CDE).

NXP200 is a paradox-breaking BRAF inhibitor designed to block the BRAF pathway without triggering paradoxical activation that is seen with first-generation BRAF inhibitors. To date, NXP200 has demonstrated single-agent clinical activity, including in heavily pre-treated patients as well as in patients previously treated with BRAF inhibitors, against primary central nervous system (CNS) tumors and other tumor types including non-small cell lung, colorectal and papillary thyroid cancers.

In June 2026, Nuvectis in-licensed exclusive worldwide, ex-Greater China rights to NXP200 from Haisco Pharmaceutical Group.

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “We congratulate our partner Haisco for achieving this significant regulatory milestone, which is further testament to its tremendous strategic and operational capabilities. The CDE’s granting of Breakthrough Therapy Designation underscores the compelling clinical activity observed to date with NXP200 in patients with recurrent or progressive BRAF V600-mutant high-grade glioma. In parallel, we continue to advance NXP200 toward a U.S. IND submission in the fourth quarter of 2026.”

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology. The Company’s pipeline includes ciprocopan (NXP100), a complement Factor B inhibitor in development for the treatment of complement-mediated diseases, and the oncology drug candidates NXP200 and NXP900, in development for the treatment of advanced cancers.

The company’s lead drug candidate is ciprocopan, a once-a-day Factor B inhibitor, with best-in-class potential, recently approved in China for the treatment of PNH patients previously untreated with complement inhibitors.

NXP200 is an oral, brain-penetrant, paradox-breaker BRAF inhibitor for the treatment of BRAF V600X-mutated and Class II/III non-V600-mutated solid tumor malignancies, with best-in-class potential.

NXP900 is an oral small molecule inhibitor of the SRC family kinases, including SRC and YES1.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws, which are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate”, “believe”, “contemplate”, “could”, “estimate”, “expect”, “intend”, “seek”, “may”, “might”, “plan”, “potential”, “predict”, “project”, “target”, “aim”, “should”, “will”, “would”, or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding future events, including statements about the approvability and market potential of our pipeline products. Forward looking statements are based on Nuvectis’ current expectations, estimates, and projections and past interpretations of data and information available, including preclinical and clinical safety, pharmacokinetics, pharmacodynamics, and efficacy data generated to date for NXP200 and the clinical and regulatory implications of a Breakthrough Therapy Designation for NXP200 in China. The outcomes of the events described in these forward-looking statements are subject to inherent uncertainties, risks, assumptions, market and other conditions, and other factors that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties may also be subject to market and other conditions and described more fully in the section titled “Risk Factors” in Nuvectis’ second quarter 2026 Form 10-Q and Nuvectis’ other public filings with the U.S. Securities and Exchange Commission (“SEC”). However, these risks are not exhaustive and new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward looking statements contained in this press release or other filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Nuvectis’ expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company Contact
Ron Bentsur
Chairman, Chief Executive Officer and President
rbentsur@nuvectis.com

Media Relations Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com

TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma”), today announced its licensee – Unbuzzd Wellness Inc. (the “Company” or “Unbuzzd“), the company behind unbuzzd™ (“unbuzzd”) — the scientifically-proven and game-changing beverage proven to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms, is pleased to announce the appointment of Mr. Michael Zapolin (“Zappy”) as CEO. This marks a pivotal milestone in the Company. His mandate includes financing and listing Unbuzzd on a stock exchange and then executing a nationwide commercial marketing and product rollout in the United States.

Zappy began his career on Wall Street, becoming one of the youngest Vice Presidents at Bear Stearns, before emerging as an early internet entrepreneur behind category-defining domains including Beer.com, Diamond.com and CreditCards.com. He later became an investor and futurist focused on emerging industries, including psychedelics and next-generation wellness. Through initiatives such as the Mushroom Investment Fund, he has backed companies across the psychedelic economy, and he co-founded KetaMD, an at-home ketamine telemedicine company acquired by Braxia Scientific in 2022. Zappy is a graduate of Boston University and Harvard Business School’s Owner/President Management Program. Playboy Magazine once dubbed Zappy Zapolin “The Man Who Wants to Change the World with Psychedelics.” He now also wants to change the world with unbuzzd.

The Company thanks Richard Buzbuzian who was Chief Executive Officer of the Company and is now assisting in the transition to a publicly listed company scheduled to go effective in the next quarter.

“In my experience, truly disruptive consumer products are built at the intersection of innovation, proven results and exceptional execution—and I believe unbuzzd has all three,” said Gerry David, Director of Unbuzzd Wellness Inc. “The clinical validation behind unbuzzd gives us something extremely powerful to bring to consumers and retailers: a product with science supporting what it says it can do. With Zappy’s entrepreneurial track record, ability to build brands and extensive network, I believe we now have the leadership to take that foundation and turn unbuzzd into a significant consumer brand. The opportunity in front of us is substantial, and I am extremely excited about what this team can accomplish.”

Clinically Validated, Science-backed Innovation

unbuzzd stands apart in the wellness and recovery supplement landscape as the only product backed by a peer-reviewed clinical study proving its efficacy in accelerating alcohol metabolism, restoring mental clarity, and reducing hangover symptoms. unbuzzd is available for sale on amazon.com and unbuzzd.com.

The peer-reviewed clinical study, which investigated the effects of unbuzzd on alcohol intoxication and alcohol metabolism, was published in the World Journal of Pharmaceutical and Medical Research (2026, volume 12, issue 3, pages 446-467). The publication can be viewed by clicking the following link:

https://zenodo.org/records/18873638

Addressing Health-Conscious Consumer Demand

The shift toward better-for-you beverages continues to accelerate, with 70% of Americans actively seeking health benefits from their beverage choices and 72% of Gen Z consumers trying new beverages monthly. unbuzzd addresses this consumer demand through a clean label approach—a proprietary blend of vitamins, minerals, and herbs developed by a world-class R&D team in pharmacology and medicine. Unlike competitors targeting only hydration or hangover symptoms, unbuzzd combines both with metabolic science in convenient ready-to-mix powder stick formats.

Scalable Platform for Multi-Channel Distribution

The Company’s growth strategy targets an expansive retail footprint including pharmacies, liquor stores, supermarkets, mass merchandisers, convenience stores, and college stores—a multi-channel distribution approach mirroring successful nationwide rollouts by industry leaders. With national distribution capabilities and a scalable platform for both retail and e-commerce, unbuzzd is positioned to capture significant share of the total addressable market for alcohol recovery and functional wellness beverages across North America and international markets.

“As unbuzzd moves to complete its listing on a stock exchange, we are pleased to announce Mr. Zapolin to lead the team,” commented Dr. Eric Hoskins, Director. “With the functional beverage market on track to exceed $198 billion and consumer demand for clinically validated, better-for-you products at an all-time high and Mr. Zapolin’s extensive network, the timing is excellent.”

“As an advocate for alternative health treatments, I got very excited about unbuzzd a couple of years ago when I heard that the science team had cracked the code” commented Mr. Zapolin, CEO, Unbuzzd Wellness. “We’ve needed something like this for as long as alcohol has been part of our society.”

Mr. Zapolin continued, “the team includes some of the most brilliant people from the beverage industry and scientific community. I believe unbuzzd has the potential to help millions of lives, and I’m honored to help bring it forward.”

About Unbuzzd Wellness Inc.

Unbuzzd Wellness Inc., a non-trading but fully reporting public issuer, stands as a pioneering force in the wellness and recovery supplement landscape. unbuzzd has been developed by a world-class R&D team in pharmacology and medicine, with a commitment to innovation and quality. A proprietary blend of vitamins, minerals, and herbs, unbuzzd helps your body process alcohol faster, restore mental alertness, and improve cognition so you can drink responsibly and drink refreshingly. unbuzzd appeals to a broad target audience of alcohol consumers who want to have a good time, be in control, and still feel great the next day.

Scientifically backed by a recently completed double-blind, randomized, placebo-controlled crossover design clinical trial, unbuzzd dramatically accelerates alcohol metabolism, speeds the reduction of blood alcohol concentration (“BAC“), restores mental clarity, and reduces the symptoms of intoxication, impairment and hangover. Key findings from the clinical trial include:

• Accelerated Alcohol Metabolism: unbuzzd dramatically and rapidly reduced blood alcohol concentration in study participants. The rate at which BAC was lowered was, on average for most participants, more than 40 percent faster within 30 minutes of consuming unbuzzd compared to control subjects.
• Rapid Improvements in Alertness: Study participants reported statistically significant improvement in alertness as soon as 30 minutes after consuming unbuzzd. Participants felt more alert and made fewer cognitive errors within 30 minutes of consuming unbuzzd, significantly outperforming placebo results.
• Rapid Improvements in Physiologic Changes due to Intoxication: unbuzzd lessened the elevation in heart rate and the drop in blood pressure that often accompanies alcohol intoxication, stabilizing both. This result was statistically significant.
• Reduced Perceived Impairment and Mental Fatigue: unbuzzd helped alleviate perceived impairment and mental fatigue caused by alcohol intoxication.
• Hangover Relief: Participants in this study noted a statistically significant reduction in hangover symptoms. This included reduced cognitive and physical impairment, and reduced headache compared to placebo results, at both four hours (67 percent reduction in headache severity) and eight hours after consuming unbuzzd.
• No Side Effects: unbuzzd was well-tolerated by all study participants, with no reported adverse side effects.

The full press release of the clinical trial can be found here.

unbuzzd ready-to-mix powder sticks are available in 3-pack, 8-pack, and 18-pack formats at https://unbuzzd.com.

Individual results may vary. unbuzzd is a dietary supplement. Consuming unbuzzd after alcohol ingestion does not permit you to operate a vehicle. Drink responsibly. DO NOT DRINK AND DRIVE.

For additional information, please contact:
Michael “Zappy” Zapolin
Chief Executive Officer
T: (617) 447-9012
E: zappy@unbuzzd.com

8–pack, 18-pack, and 3-pack formats of the unbuzzd ready-to-mix powder sticks
To view an enhanced version of this graphic, please visit: link

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.48% (as of June 30, 2026) of Unbuzzd. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

For more information visit www.quantumbiopharma.com.

Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable Canadian securities laws. Forward-looking information is generally, but not always, identified by words such as “anticipates,” “believes,” “expects,” “intends,” “plans,” “potential,” “proposes,” “estimates,” “may,” “could,” “would,” “will” and similar expressions. Forward-looking information in this news release includes, but is not limited to, statements regarding the Company’s plans to seek financing and a listing of its securities on a stock exchange; the timing and completion of any such financing or listing; the Company’s planned nationwide commercial marketing and product rollout in the United States; expansion of retail, e-commerce and other distribution channels; the Company’s ability to scale its platform and operations; potential market opportunities and consumer demand for unbuzzd; and the Company’s expectations regarding the future commercialization, distribution, adoption and performance of unbuzzd.

Forward-looking information is based on management’s current expectations, estimates, projections, assumptions and beliefs as of the date of this news release, including assumptions regarding the availability of financing on acceptable terms; the Company’s ability to satisfy applicable regulatory, securities exchange and other requirements for a listing; favourable market and economic conditions; the continued availability and performance of key personnel, suppliers, distributors and strategic partners; the Company’s ability to manufacture and distribute products at commercial scale; continued consumer demand for functional wellness products; the accuracy and applicability of market data and third-party research; and the Company’s ability to execute its business, marketing and commercialization plans.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking information. These risks and uncertainties include, among others, the Company’s early stage of commercialization; the availability and cost of capital; the risk that a financing or stock exchange listing may be delayed, completed on different terms or not completed at all; regulatory requirements applicable to the Company, its products, product claims, labelling, marketing and distribution; changes in applicable laws and regulations; the Company’s ability to protect its intellectual property; competition and the introduction of competing products; reliance on key personnel, suppliers, manufacturers, distributors and other third parties; manufacturing, supply-chain and distribution disruptions; product liability and consumer acceptance risks; the ability to achieve anticipated sales, distribution and market penetration; and general economic, financial market and industry conditions.

Although the Company believes that the assumptions and expectations reflected in such forward-looking information are reasonable, there can be no assurance that they will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Actual results and future events could differ materially from those anticipated in such information.
The forward-looking information contained in this news release is made as of the date hereof. Except as required by applicable securities laws, the Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

The Company does not represent that unbuzzd prevents, treats or cures any disease or medical condition. unbuzzd is a dietary supplement, and statements regarding its effects are subject to the limitations described in the referenced clinical study and may not apply to every individual. The U.S. Food and Drug Administration, Health Canada and other similar regulatory authorities have not evaluated or approved unbuzzd for the diagnosis, treatment, cure or prevention of disease. Individual results may vary. Consuming unbuzzd after alcohol ingestion does not make it safe or lawful to operate a motor vehicle or engage in any activity requiring sobriety. Drink responsibly. DO NOT DRINK AND DRIVE.

Contacts:

Investor Relations
Robert Guzman, Investor Relations
Email: Rob@QuantumBioPharma.com  
Telephone: (833) 304-0323
General Inquiries: info@QuantumBioPharma.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/59611581-4786-49a7-918d-b18dd32889b0

TORONTO, Ontario, Sept. 24, 2026 (GLOBE NEWSWIRE) — Cadillac Mines Corporation (TSX: CADY), (“Cadillac Mines” or the “Company“) is pleased to announce the addition of Pierre Beaudoin to the Company’s Board of Directors. Jaime Hartman, a current Director and original founder of the Company, has resigned from the Board to facilitate Mr. Beaudoin’s appointment.

Mr. Beaudoin is a mineral processing professional with 40 years of international operating and project development experience. Most recently, Pierre was Chief Operating Officer of SilverCrest Metals Inc., where he successfully led the technical studies, construction, and ramp-up of the Las Chispas Mine in Mexico, delivering the project ahead of schedule, below budget during the pandemic, and with an efficient and rapid ramp-up to commercial production. Prior to SilverCrest, Mr. Beaudoin worked as Senior Vice President, Capital Projects, followed by Chief Operating Officer, with Detour Gold Corporation, during which time he was involved in the construction and operation of the Detour Lake Mine, now the largest gold mine in Canada. He also held capital projects and management roles with Barrick Gold Corporation. He currently serves as Chairman of Radisson Mining Resources Inc. and is a Director of Coeur Mining Inc.

Chairman of Cadillac Mines, Pierre Lassonde commented: “On behalf of the Board, I am very pleased to welcome Pierre as a Director of the Company. His experience developing and operating mines, particularly in Ontario and Quebec, is a perfect fit for our portfolio of assets. More broadly, his technical expertise and deep knowledge of the mining industry further strengthen our Board and provides tremendous value to our shareholders.” Mr. Lassonde continued, “On behalf of the entire Company, I would like to thank Jaime for all that he contributed over the last 11 years. His commitment and professionalism have been integral in getting Cadillac Mines to where it is today – thank you Jaime.”

About Cadillac Mines

Cadillac Mines Corporation is a Canadian mineral exploration company advancing a growing portfolio of gold and critical mineral projects along the prolific Cadillac-Larder Lake Break in Ontario and Québec. Anchored by the historic Kerr-Addison Mine, the Company is focused on expanding its gold resource base, advancing the Geminid nickel deposit and unlocking the broader potential of its district-scale Abitibi land position. Through disciplined exploration, technical excellence and responsible development, Cadillac Mines is working to create lasting value for shareholders, communities and other stakeholders. For more information about the Company, please visit www.cadillacmines.com.

Additional Information

For further information, please contact:

Hannes Portmann, Chief Financial Officer
hportmann@cadillacmines.com

In a preclinical chronic colitis model, Tvardi’s oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma, at pharmacologically relevant levels, and modulated STAT3-driven disease biology 

Collective findings now span multiple preclinical models of UC, further supporting the scientific rationale for advancing TTI-109, Tvardi’s next-generation STAT3 inhibitor, in UC

HOUSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) — Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced the publication of preclinical data evaluating Tvardi’s STAT3 inhibitor in the International Journal of Molecular Sciences. The publication provides additional evidence supporting further investigation of STAT3 inhibition as a potential therapeutic approach to treating inflammatory bowel diseases, including ulcerative colitis (UC).

The publication, titled “Colitis-Associated Colorectal Cancer—STAT3 Inhibition as a Preventive Strategy,” evaluated Tvardi’s first-generation oral STAT3 inhibitor, TTI-101, in an azoxymethane (AOM)-dextran sodium sulfate (DSS) mouse model, designed to replicate the human progression from chronic colitis to colorectal cancer (CRC). Patients with UC are estimated to have a 20- to 30-fold higher risk of CRC than the general population. In this model, the orally administered STAT3 inhibitor reached pharmacologically relevant concentrations in the colon, normalized STAT3-regulated colonic gene expression and modulated proliferative programs associated with colitis-driven disease progression, preventing the development of colon polyps and adenocarcinomas. The chronic AOM-DSS prevention model is the fourth preclinical model of colitis in which Tvardi’s STAT3 inhibitors have shown biological activity. Previously, Tvardi’s oral small molecules normalized the UC hallmarks of immune dysregulation, inflammation and proliferation across three acute models representing distinct immune axes: DSS (innate/Th17), trinitrobenzene sulfonic acid (TNBS; adaptive Th1) and oxazolone (OXA; adaptive Th2/NKT).

“UC is a multifactorial disease shaped by three interconnected processes: immune dysregulation, inflammation and proliferation, each of which is regulated by STAT3. Current advanced therapies are designed primarily to target inflammation,” said Imran Alibhai, Ph.D., Chief Executive Officer of Tvardi Therapeutics. “Even patients who reach endoscopic remission are not disease-free: 98% retain lesions composed of B- and T-cell aggregates, inflammatory infiltrates and distorted crypts associated with the chronic disease characteristics of UC. In this preclinical model, oral STAT3 inhibition achieved high exposure in the colon and normalized gene expression spanning unique STAT3-regulated programs associated with relapse and progression. We believe these findings demonstrate the potential of STAT3 inhibition in modulating multiple aspects of the underlying disease biology with a profile favorable for gastrointestinal indications requiring high mucosal drug exposure.”

Findings relevant to UC include:

• High colon exposure: TTI-101 achieved approximately 8-fold higher drug levels in the colon than in plasma, indicating accumulation in the target organ, at pharmacologically relevant levels for inhibition of STAT3-dependent proliferation.
• Broad effects on disease-associated gene expression: TTI-101 reversed many disease-induced changes in colon gene expression, including genes associated with colorectal cancer and STAT3 signaling. The normalized genes span the principal axes of UC biology: regulators of cellular immune responses, including recognized IBD/UC susceptibility genes, components of the humoral immune response, inflammatory and acute-phase mediators and epithelial-barrier and proliferative genes. Normalizing gene expression across these interacting programs, rather than blocking a single mediator, supports the potential of STAT3 inhibition to interrupt the chronic disease process.
• TTI-101 prevented tumors from forming: TTI-101 prevented adenocarcinoma formation entirely (p≤0.05), while pY-STAT3 (activated STAT3) was found to be elevated in the tumors that developed in vehicle-treated animals. TTI-101 reached levels more than 20 times the STAT3 IC₅₀ (the concentration needed to block STAT3-driven growth) in the colon. These prevention results build on earlier work in the chronic AOM-DSS treatment model¹, in which TTI-101, given as treatment after colitis was established, achieved high drug exposure in the colon and statistically significantly reduced tumor formation.

Addressing the chronic nature of UC: UC is a chronic, relapsing disease driven by three linked, STAT3-regulated processes: immune dysregulation, inflammation and proliferation. Current advanced therapies are directed primarily at inflammation, and placebo-adjusted clinical remission rates remain below 30%. Genetic and pharmacologic studies have implicated activated STAT3 in the severity of colitis; pY-STAT3 inhibition has shown activity across both short- and long-term treatment settings. In three acute models representing distinct immune axes of UC, TTI-101/TTI-109 statistically significantly reduced immune dysregulation, diarrhea, colonic inflammation, colon shortening and pY-STAT3 in the colon. In the longer-term AOM-DSS model, TTI-101 demonstrated activity after colitis was established. In the present study, after ten weeks of continuous dosing in mouse models, TTI-101 sustained normalization of the colon transcriptome and prevented the development of colon adenocarcinomas, a long-term consequence of chronic colitis. Across Tvardi’s clinical data, STAT3 inhibition modulated the same three-part signature: reduced key immune cell populations in healthy volunteers, reduced IL-6, a central pro-inflammatory cytokine that signals through STAT3, and reduced fibrosis score in patients with idiopathic pulmonary fibrosis. Taken together, these findings suggest the potential for STAT3 inhibition to act on the underlying biology leading to and driving the chronic nature of UC.

“Building on our experience with TTI-101, we developed TTI-109 as a next-generation prodrug designed to preserve TTI-101’s STAT3-targeting mechanism while improving drug delivery and tolerability. Our recently completed Phase 1 healthy volunteer study of TTI-109 demonstrated predictable pharmacokinetics, favorable GI tolerability and modulation of UC-relevant immune cell populations, which we believe further supports our development in UC,” Dr. Alibhai concluded.

The publication can be found here.

1. Robinson P, et al. STAT3 Inhibition to Treat Ulcerative Colitis-Associated Colorectal Cancer. Int J Mol Sci. 2025;26(21):10808.

About Tvardi Therapeutics

Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need. STAT3 is a central mediator across critical signaling pathways that drive uncontrolled proliferation, survival and immune dysregulation. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The Company has completed a Phase 1 healthy volunteer study of TTI-109 and plans to initiate clinical trials of TTI-109 in gastrointestinal (GI) diseases pending IND clearance and the availability of additional funding. The Company is also conducting a Phase 1b/2 clinical trial of TTI-101 in hepatocellular carcinoma (NCT05440708). To learn more, please visit tvarditherapeutics.com or follow us on LinkedIn and X (Twitter).

Contacts:

For Tvardi:
Tvardi Investor Relations
ir@tvardi.com

PJ Kelleher
LifeSci Advisors
617-430-7579
pkelleher@lifesciadvisors.com

Cautionary Statement Regarding Forward-looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the anticipated benefits of Tvardi’s product candidates, including TTI-101 and TTI-109 in UC and of the Company’s STAT3 inhibitors, including in modulating underlying UC disease biology; the potential benefits of TTI-109 as compared to TTI-101, including improved delivery and tolerability; its ongoing and planned clinical trials; the results from preclinical models of UC supporting the advancement of TTI-101 and TTI-109 into future clinical trials; the Company’s plans to develop TTI-109 in UC; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them.

Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are subject to a number of risks, including, among other things: the uncertainties associated with Tvardi’s product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the completion of clinical trials or safety or other complications related to its product candidates; the ability to replicate the positive results from preclinical studies or early clinical trials in future clinical trials; the ability to obtain IND clearance for TTI-109 in GI therapeutic areas on the timelines expected or at all; the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all; the significant net losses Tvardi has incurred since inception; Tvardi’s ability to initiate and complete ongoing and planned preclinical studies and clinical trials and advance its product candidates through clinical development; the timing of the availability of data from Tvardi’s clinical trials; the outcome of preclinical testing and clinical trials of Tvardi’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; Tvardi’s plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of Tvardi’s product candidates; the estimated patient populations and total addressable markets for the indications in which Tvardi seeks to develop its product candidates; Tvardi’s anticipated cash runway; Tvardi’s ability to attract, hire, and retain skilled executive officers and employees; Tvardi’s ability to protect its intellectual property and proprietary technologies; Tvardi’s reliance on third parties, contract manufacturers and contract research organizations; the possibility that Tvardi may be adversely affected by other economic, business or competitive factors; risks associated with changes in applicable laws or regulations; those factors discussed in Tvardi’s filings with the Securities and Exchange Commission, including the “Risk Factors” section of the Annual Report on Form 10-K for the year ended December 31, 2025, and Tvardi’s other documents subsequently filed with or furnished to the SEC, all of which are available on the SEC’s website at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

VANCOUVER, British Columbia, Sept. 24, 2026 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, announces that its drone subsidiary ZenaDrone has advanced its defense-focused quantum navigation system, which is designed to enable secure drone operations in GPS-denied and satellite-compromised environments, to the testing phase. Testing is now underway at ZenaDrone’s manufacturing and testing facilities in Sharjah, UAE, where the company’s engineering team is working to validate the system’s navigation accuracy and reliability under real-world flight conditions. Initial testing is beginning with the IQ Nano indoor drone platform in non-GPS environments, with the team preparing to move to field testing on the ZenaDrone 1000, the company’s AI multifunction heavy-lift cargo defense drone, as well as its other drone platforms.

“Operating reliably when GPS and satellite navigation are degraded, denied, or spoofed is a mission-critical requirement for modern defense operations,” said Shaun Passley, Ph.D., ZenaTech CEO. “As the ZenaDrone 1000 is fielded in defense applications, redundant, multi-layered navigation will be essential. Operators need confidence that a platform can maintain position, navigation, and timing (PNT), even if one system is jammed, spoofed, or otherwise fails in a contested environment. Advancing our quantum navigation system into testing is a key milestone toward delivering that redundancy and mission assurance to future defense customers.”

Quantum navigation systems represent a next-generation class of self-contained, ultra-precise motion-sensing technology that allows drones and other platforms to maintain accurate navigation without relying on GPS, instead using principles derived from quantum physics. As modern defense missions increasingly operate in contested electromagnetic environments where adversaries may jam or spoof satellite signals, these systems combine quantum inertial sensing with AI-based path correction to deliver continuous, high-precision positioning over long mission durations, independent of external signals. Beyond defense, the technology also holds promise for commercial drone operators working in GPS-challenged settings, including dense urban corridors, indoor warehouses, underground facilities, and extended BVLOS (Beyond Visual Line-of-Sight) missions.

Having advanced beyond the initial research and development stage, ZenaDrone’s engineering team is now in the testing and validation phase of the program, with cross-functional teams collaborating on drone integration ahead of broader field trials. Once validated, the quantum navigation system is expected to be incorporated across selected ZenaDrone defense and commercial drone platforms, extending capabilities in areas such as surveillance, critical infrastructure inspection, and defense missions.

Built as an advanced, AI-enabled VTOL heavy-lift platform for defense use, the ZenaDrone 1000 delivers ISR capabilities such as real-time surveillance, tactical reconnaissance, and secure data collection, in addition to cargo transport and mission-critical payload delivery. Its modular architecture enables rapid reconfiguration for a range of mission types in high-risk operating environments, from infrastructure monitoring to operational logistics support.

About ZenaTech

ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company that specializes in AI autonomy drone platforms to transform commercial, government, and defense sectors. Its subsidiaries include drone manufacturing through ZenaDrone, a global Drone as a Service (DaaS) business, and an enterprise SaaS division of software brands. The Company is executing an acquisition-led DaaS roll-up strategy to digitize and automate legacy service industries including land surveys and inspections, driving drone-based scalable and recurring revenue growth. With an operating footprint spanning North America, Europe, the Middle East, Asia, and Australia, ZenaTech is advancing AI drones for agriculture and logistics, as well as ISR, cargo, and counter-UAS applications for U.S. defense and NATO allies. The company is investing in next-generation technologies, including drone swarms, quantum computing, and advanced AI autonomy to capture long-term opportunities in key markets through its R&D initiatives.

About ZenaDrone

ZenaDrone, a subsidiary of ZenaTech, develops and manufactures AI-powered multifunction autonomous drone solutions integrating machine learning, predictive analytics, and advanced computing technologies, for government, defense, and industrial applications. This includes multifunctional drones for surveying, inspections, logistics, security, and defense applications. Its product portfolio includes the ZenaDrone 1000 for ISR defense and specialized cargo, the IQ Nano for indoor inventory management and security, the IQ Square for outdoor inspections and maintenance, the IQ Quad for land surveying, and the IQ Aqua for underwater applications. ZenaDrone operates three global manufacturing facilities in Arizona, Dubai, and Taiwan, and is advancing counter-UAS maritime interceptor drones and an integrated defense system.

Contacts for more information:

Company, Investors, and Media:
Linda Montgomery
ZenaTech
312-241-1415

Investors:
Michael Mason
CORE IR
investors@zenatech.com

Safe Harbor

This press release and related comments by management of ZenaTech, Inc. include “forward-looking statements” within the meaning of U.S. federal securities laws and applicable Canadian securities laws. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. This forward-looking information relates to future events or future performance of ZenaTech and reflects management’s expectations and projections regarding ZenaTech’s growth, results of operations, performance, and business prospects and opportunities. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “aim”, “seek”, “is/are likely to”, “believe”, “estimate”, “predict”, “potential”, “continue” or the negative of these terms or other comparable terminology intended to identify forward-looking statements. Forward-looking information in this document includes, but is not limited to ZenaTech’s expectations regarding its revenue, expenses, production, operations, costs, cash flows, and future growth; expectations with respect to future production costs and capacity; ZenaTech’s ability to deliver products to the market as currently contemplated, including its drone products including ZenaDrone 1000, IQ Square, IQ Nano, IQ Quad, ZenaTech 2000, IQ Glider, IQ Sphere, IQ Aqua and Interceptor P-1; ZenaTech’s ability to develop products for markets as currently contemplated; ZenaTech’s anticipated cash needs and its needs for additional financing; ZenaTech’s intention to grow the business and its operations and execution risk; expectations with respect to future operations and costs; the volatility of stock prices and market conditions in the industries in which ZenaTech operates; political, economic, environmental, tax, security, and other risks associated with operating in emerging markets; regulatory risks; unfavorable publicity or consumer perception; difficulty in forecasting industry trends; the ability to hire key personnel; the competitive conditions of the industry and the competitive and business strategies of ZenaTech; ZenaTech’s expected business objectives for the next twelve months; ZenaTech’s ability to obtain additional funds through the sale of equity or debt commitments; investment capital and market share; the ability to complete any contemplated acquisitions; changes in the target markets; market uncertainty; ability to access additional capital, including through the listing of its securities in various jurisdictions; management of growth (plans and timing for expansion); patent infringement; litigation; applicable laws, regulations, and any amendments affecting the business of ZenaTech and other related risks and uncertainties disclosed under the heading “Risk Factors” in the Company’s Form F-1, Form 20-F and other filings filed with the United States Securities and Exchange Commission (the “SEC”) on EDGAR through the SEC’s website at www.sec.gov. The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.

Oral Presentations Highlight Phase 2 Vision Protection and Enrollment of a Consistent Phase 3 Patient Population Well-Positioned to Replicate Phase 2 Vision Outcomes

ARCHER II is the First Pivotal Trial Designed to Demonstrate Protection of Vision in Geographic Atrophy, with Month 15 Results Expected in the Fourth Quarter of 2026

BRISBANE, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced two oral presentations on vonaprument at The Retina Society 59th Annual Scientific Meeting being held September 23-26, 2026 in Los Angeles, California.

​Geographic atrophy (GA) is a neurodegenerative eye disease and leading cause of blindness affecting more than 8 million people worldwide. GA gradually destroys the central vision patients need to read, drive, recognize faces, and maintain independence.

Upcoming oral presentations highlight vision protection findings in diverse GA patient populations in the Phase 2 ARCHER study that informed the design and execution of the ongoing Phase 3 ARCHER II trial. Presentations highlight the replication of key baseline clinical characteristics between the Phase 2 and Phase 3 patient populations, an important strategy to position the Phase 3 trial to confirm the potential of vonaprument to protect vision across a broad population of patients with GA.

Oral Presentation Details

“Baseline Characteristics of Participants in the Phase 3 ARCHER II Trial in Dry AMD With GA”

• Presenter: Ashkan Abbey, M.D., Texas Retina Associates
• Date/Time: Friday, September 25, 2026 at 9:10 a.m. PT

“Vision Outcomes in Eyes with Subfoveal RPE Lesions in Geographic Atrophy: A Post Hoc Analysis of the Phase 2 ARCHER Trial”

• Presenter: Mark Barakat, M.D. FASRS, Retina Macula Institute of Arizona
• Date/Time: Friday, September 25, 2026 at 9:13 a.m. PT

Presentations can be found on the publications page of Annexon’s website following the meetings.

About Vonaprument (formerly ANX007)
Vonaprument is a clinical-stage investigational antigen-binding fragment (Fab) designed as a first-in-kind therapeutic to selectively inhibit C1q, the initiating molecule of the classical complement pathway and a key driver of neurodegeneration. It is formulated for intravitreal (IVT) administration, with the potential to be the first targeted vision-protecting therapy for GA. Vonaprument involves a differentiated neuroprotective approach designed to protect photoreceptor cells and retinal function by blocking C1q and the entire classical pathway, while allowing for normal immune activity of the lectin and alternative complement pathways. Vonaprument has been granted Fast Track designation from the U.S. Food and Drug Administration (FDA) and is the first therapeutic candidate for the treatment of GA to receive Priority Medicine (PRIME) designation from the European Medicines Agency (EMA) for the treatment of GA.

About the ARCHER Clinical Program
ARCHER (NCT04656561) is a completed Phase 2 trial that evaluated vonaprument in a broad population of patients with GA. Vonaprument consistently protected visual function and ellipsoid zone retinal structure across multiple measures, providing significant, time- and dose-dependent protection from vision loss as measured by confirmed best corrected visual acuity (BCVA) ≥15-letter loss. It was generally well-tolerated through month 12, with no increase in choroidal neovascularization (CNV) rates versus sham and no events of retinal vasculitis. ARCHER II (NCT06510816) is an ongoing global Phase 3 trial in 659 patients that was designed to replicate the findings of ARCHER, with confirmed BCVA ≥15-letter loss as the primary endpoint measured through months 15 and 24. A global registration path has been established with U.S. and European regulators. ARCHER II is a single protocol that will also be analyzed as two sub-studies after meeting the primary endpoint. Results from the month 15 primary analysis are expected in the fourth quarter of 2026.

About Annexon
Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “suggest,” “target,” “on track,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, the potential therapeutic benefit of vonaprument and the timing of results of ongoing clinical trials of vonaprument. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the ongoing off-treatment follow-up portion of the ARCHER trial and final results from the ARCHER trial; the company’s history of net operating losses; the company’s ability to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the company’s product candidates; the effects of public health crises on the company’s clinical programs and business operations; the company’s ability to obtain regulatory approval of and successfully commercialize its product candidates; any undesirable side effects or other properties of the company’s product candidates; the company’s reliance on third-party suppliers and manufacturers; the outcomes of any future collaboration agreements; and the company’s ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail under the section titled “Risk Factors” contained in the company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the company’s other filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Media Contact:
Christian Vaughn
annexonpr@syneoshealth.com

VANCOUVER, British Columbia, Sept. 24, 2026 (GLOBE NEWSWIRE) — COLLECTIVE METALS INC. (CSE: COMT | OTC: CLLMF | FSE: TO1) (the “Company” or “Collective Metals”) is pleased to announce the appointment of Curtis Riou, P.Geo., to its Board of Directors, effective September 23, 2026.

Mr. Riou is a Professional Geoscientist with more than 25 years of experience in environmental consulting and resource development across Canada’s oil, gas and mining sectors. He serves as Chief Operating Officer of Apex Exploration and is a co-founder of X-Terra Environmental Services Ltd., a First Nation–owned environmental consulting firm.

His background combines project management with environmental and regulatory expertise, bringing a practical perspective to the planning and oversight of resource projects.

“We are pleased to welcome Curtis to Collective Metals’ Board of Directors,” said Ram Kumar, Chief Executive Officer of Collective Metals. “His experience in resource development and environmental management will strengthen the board as we assess our exploration priorities and evaluate opportunities for the Company. We look forward to working with Curtis to establish a practical path forward for our portfolio.”

About Collective Metals

Collective Metals Inc. (CSE: COMT | OTC: CLLMF | FSE: TO1) is a resource exploration company specializing in critical and precious metals exploration in North America.

The Company’s Rocas project comprises 4,002 hectares, located 75 kilometers southwest of the Key Lake Mine and Mill facilities along Highway 914, and approximately 72 kilometers south of the present-day margin of the Athabasca Basin. The Project hosts several uranium showings, including historical mineralized outcrop grab samples along approximately 900 metres of strike length, grading up to 0.5 wt.% U₃O₈¹.

Social Media 

X	@COMT_metals
LinkedIn	Collective Metals Inc
Facebook	Collective Metals Inc

ON BEHALF OF COLLECTIVE METALS INC.
Ram Kumar, Chief Executive Officer

Forward-Looking Statements

This news release includes “forward-looking information” under applicable Canadian securities legislation. Such forward-looking information includes, but is not limited to, statements regarding the management changes. Such information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information, including, but not limited to: general business, economic, competitive, political and social uncertainties; the risk that the Canadian Securities Exchange does not accept the appointment; the loss of key personnel; and other risks common to the mining industry. Readers are cautioned that the foregoing list is not exhaustive.

The Company is an exploration stage company. Exploration is highly speculative in nature, involves many risks, and may not result in the discovery of mineral deposits that can be mined profitably. The Company has no mineral reserves on any of its properties. Consequently, there can be no assurance that forward-looking statements will prove to be accurate, and actual results and future events could differ materially. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

SINGAPORE, Sept. 24, 2026 (GLOBE NEWSWIRE) — Trident Digital Tech Holdings Ltd (“Trident” or the “Company”) has received a notification letter, dated September 22, 2026, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that the Company’s market value of listed securities (“MVLS”) has been US$35,000,000 or greater for the last 10 consecutive business days, from September 8, 2026 to September 21, 2026. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(b)(2) and this matter is now closed.

On March 26, 2026, the Company received a notification letter from the Listing Qualifications Department of Nasdaq, indicating that, based upon the Company’s MVLS for the 34 consecutive business day period from February 5, 2026 through March 20, 2026, the Company did not maintain the minimum MVLS of US$35,000,000 required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2). The Company was afforded a period of 180 calendar days, or until September 22, 2026, to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(C).

About Trident Digital Tech Holdings Ltd.

Trident Digital Tech Holdings Ltd. (Nasdaq: TDTH) is a Singapore-headquartered digital infrastructure holding company focused on building and operating sovereign-scale technology platforms across emerging markets. The Company’s strategy centers on entering high-growth economies through trusted digital identity infrastructure and expanding across adjacent government technology, digital commerce, cybersecurity, AI, and transaction-driven service verticals.

TDTH’s active initiatives include national digital identity infrastructure mandates, MSME digital tax formalization platforms, national digital commerce ecosystems, and enterprise cybersecurity deployments spanning Africa and the Asia-Pacific region. Through strategic partnerships, joint ventures, acquisitions, and technology-driven platform deployment, TDTH aims to establish scalable long-term digital infrastructure ecosystems serving both public and private sector markets.

With active operations and strategic initiatives in the Democratic Republic of Congo, Ghana, and Asia-Pacific markets, TDTH is positioning itself to capitalize on one of the largest global opportunities in digital transformation infrastructure.

Website: https://tridentity.me

Forward-Looking Statements

This announcement contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “targets,” “projects,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” “potential,” “continue,” and similar statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in announcements and other written materials, and in oral statements made by its officers, directors, or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs, plans and expectations, are forward-looking statements. This announcement contains forward-looking statements regarding the Company’s strategic initiatives, expansion plans, projected market opportunities, anticipated platform adoption, onboarding targets, projected revenue opportunities, operational deployment expectations, platform scalability, monetization opportunities, AI integration opportunities, strategic partnerships, potential acquisitions, regulatory developments, government contracting processes, and future business performance.

Forward-looking statements involve inherent risks and uncertainties, many of which are beyond the Company’s control. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: materialization and implementation of the Company’s strategic initiatives; potential adverse reactions or changes to business relationships; adverse changes in general economic or market conditions; any actions by third parties including government agencies; the expected growth of the digital solutions market; cybersecurity risks; the geopolitical, economic, social and legal developments in the jurisdictions that the Company operates in or in which the Company intends to expand its business and operations; the Company’s ability to maintain and enhance its brand. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided in this announcement is as of the date of this announcement, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

CONTACT: PR & Media Contact:

Phoenix MGMT & Consulting
Press@PhoenixMGMTConsulting.com
888-228-0122

Investor Relations Inquiries:

Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Office: (646) 893-5835
Email: investor@tridentity.me